Post by Novotech

Early-phase development strategies are increasingly being designed with global scalability in mind from day one, particularly as sponsors balance investor expectations, capital efficiency, and compressed timelines. At the Australian Clinical Trial Seminar in Chengdu, Marina Mullins, Vice President, Early Clinical Development at Novotech, presented: The Fast Lane to PoC: Leveraging Australia for Smarter Early Clinical Development The session explored how sponsors are leveraging Australia’s clinical trial environment to accelerate Phase I–II programs through faster study activation, operational flexibility, and globally recognized clinical data. A key discussion point was how early clinical strategy and long-term global development planning are becoming increasingly interconnected, particularly across cross-border China-Australia development pathways. Want to learn more? Connect with one of our experts - https://lnkd.in/gXTZ9KiE #ClinicalTrials #EarlyPhase #Biotech #DrugDevelopment